iconstar paper   HBV Articles  
Back grey arrow rt.gif
 
 
LB/O99: 48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy (Global Hepatitis Summit 2023 Paris April 28)
 
 
 

0502231

0502232

0502233

0502234

0502235

0502236

0502237

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org